So should Arvinas (NASDAQ:ARVN) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ...

Price Action: ARVN stock is down 4.93% at $6.56 at the last check on Friday.

Minister of Foreign Affairs of the Republic of Lithuania Kęstutis Budrys arrived in Ukraine on Tuesday. "Arrived to free Kyiv to express Lithuania’s unwavering support to brave Ukrainian nation. We ...

Arvinas, Inc. (NASDAQ: ARVN) recently presented data from the first-in-human clinical trial of arv-102, the company’s investigational proteolysis targeting chimera (protac) leucine-rich repeat kinase ...